Skip to content
Triangle logo TriangleGet started
← Study library

NCT02720510 · REGISTRY CONDITION SEARCH

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2018-07-24

This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion. Patients were to enroll at approximately 20 centers in the United States. Patients were to undergo stem cell mobilization with plerixafor plus Granulocyte Colony Stimulating Factor (G-CSF), according to investigator discretion, after 4 cycles of induction therapy. Study treatment interruption for stem cell collection were not to exceed 30 days. All patients were to receive one additional cycle of study treatment after stem cell collection and then proceed to autologous transplant using melphalan 200mg/m2(140mg/m2 for patients \> 70 years), as conditioning. After Autologus Stem Cell Transplant( ASCT), patients still on study were to initiate maintenance therapy within the 60-120 day period following ASCT, provided they have adequate blood count and clinical recovery. Patients in the RVD arm were to initiate maintenance therapy with lenalidomide alone, and patients in RVD-panobinostat arm were to receive lenalidomide + panobinostat maintenance. Lenalidomide were to be dosed orally at 10mg/day continuously in both arms, increasing to 15mg/day after the first 84 day cycle. Panobinostat were to be dosed at 10mg three times a week, every other week. Total planned duration of maintenance therapy were to be 3 years. Patients were to remain on study treatment until they complete the maintenance phase, or until they experience disease progression, unacceptable toxicity, or at the discretion of the Investigator.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients

→

outcome · POSTED

Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing

→

outcome · POSTED

Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance

→

outcome · POSTED

Depth of Response by International Myeloma Working Group (IMWG) Criteria

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Key Inclusion Criteria: * Patient newly diagnosed with multiple myeloma, based on following IMWG 2014 definition (Rajkumar et al 2014): * Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events: * Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder * Any one or more of the following biomarkers of malignancy: 1. Clonal bone marrow plasma cell percentage ≥ 60% 2. Involved: uninvolved serum free light chain ratio ≥ 100 3. \>1 focal lesions on MRI studies * Patient with measurable disease defined by at least 1 of the following conditions present at screening: * Serum M-protein by Protein Electrophoresis (PEP) ≥ 1.0 g/dL (≥ 10 g/L). * Urine M-protein by PEP ≥ 200 mg/24 hours. Involved serum free light chain level ≥ 10 mg/dL (≥ 100 mg/L), provided that the serum free light chain ratio is abnormal. * Patient eligible for autologous stem cell transplantation based on the investigator's clinical judgment. * Patient with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 * Patient's age ≥ 18 and \<75 years at time of signing the informed consent * Patient provided written informed consent prior to any screening procedures * Women of childbearing potential (WOCBP) with a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline Key Exclusion Criteria: Patients eligible for this study must not meet any of the following criteria: * Any concomitant anti-cancer therapy (other than bortezomib/lenalidomide/dexamethasone; bisphosphonates are permitted only if commenced prior to the start of screening period) * Unresolved diarrhea ≥ CTCAE grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease). * Allogeneic stem cell transplant recipient presenting with graft versus host disease either active or requiring immunosuppression * Patient shown intolerance to bortezomib or to dexamethasone or components of these drugs or has any contraindication to one or the other drug, following locally applicable prescribing information * Patient with rade ≥ 2 peripheral neuropathy or grade 1 peripheral neuropathy with pain on clinical examination at screening * Patient received prior treatment with DAC inhibitors including Panobinostat * Patient needing valproic acid for any medical condition during the study or within 5 days prior to first administration of panobinostat/study treatment. * Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted only if commenced prior to the start of screening period) * Patient who received: 1. prior anti-myeloma chemotherapy or medication including Immunomodulator (IMiDs) and Dex ≤ 3 weeks prior to start of study. 2. experimental therapy or biologic immunotherapy including monoclonal antibodies ≤ 4 weeks prior to start of study. 3. prior radiation therapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior start of study. * Patient has not recovered from all therapy-related toxicities associated with above listed treatments to \< grade 2 CTCAE. * Patient undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy to \< grade 2 CTCAE * Patients with evidence of mucosal or internal bleeding * Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 month prior to screening) * Inability to determine the Fridericia's Correction Formula (QTc) F interval * Patient with an impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of panobinostat (e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach and/or small bowel resection) * Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for 6 months after stopping treatment * Pregnant or nursing (lactating) women.
healthy Volunteers
false
maximum Age
74 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Revlimid, Velcade, dexamethasone and Farydak
    intervention Names
    1. Drug: Revlimid
    2. Drug: Velcade
    3. Drug: dexamethasone
    4. Drug: Farydak
    label
    Arm 1 - RVD + Pan
    type
    ACTIVE_COMPARATOR
  2. description
    Revlimid, Velcade and Dexamethasone
    intervention Names
    1. Drug: Revlimid
    2. Drug: Velcade
    3. Drug: dexamethasone
    label
    Arm 2 - RVD
    type
    ACTIVE_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm 1 - RVD + Pan
    2. Arm 2 - RVD
    description
    Revlimid was used with dexamethasone to treat patients with multiple myeloma
    name
    Revlimid
    other Names
    1. lenalidomide
    type
    DRUG
  2. arm Group Labels
    1. Arm 1 - RVD + Pan
    2. Arm 2 - RVD
    description
    Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
    name
    Velcade
    other Names
    1. bortezomib
    type
    DRUG
  3. arm Group Labels
    1. Arm 1 - RVD + Pan
    2. Arm 2 - RVD
    description
    Dexamethasone was a steroid used to treat patients with multiple myeloma.
    name
    dexamethasone
    other Names
    1. Decadron
    type
    DRUG
  4. arm Group Labels
    1. Arm 1 - RVD + Pan
    description
    FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
    name
    Farydak
    other Names
    1. panobinostat, LBH589
    type
    DRUG
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
6
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients
    time Frame
    84 days
secondary Outcomes
  1. description
    MRD negativity by Clonal Sequencing (ClonoSEQTM) assay (Adaptive Biotechnologies)
    measure
    Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing
    time Frame
    Month 3
  2. description
    ORR (CR + PR) and MRD negativity after ASCT and maintenance
    measure
    Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance
    time Frame
    Month 3 up to end of study, approximately 3 years.
  3. description
    Rate of Very Good Partial Response (VGPR), Complete Response (CR) and Stringent Complete Response (sCR)
    measure
    Depth of Response by International Myeloma Working Group (IMWG) Criteria
    time Frame
    Day 22 up to end of study, approximately 3 years
  4. measure
    Duration of Response
    time Frame
    From measurable response to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
  5. measure
    Overall Survival
    time Frame
    3 years after the last patient is enrolled to the study
  6. measure
    Progression Free Survival
    time Frame
    3 years after the last patient is enrolled to the study
Full study description
brief Summary
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion. Patients were to enroll at approximately 20 centers in the United States. Patients were to undergo stem cell mobilization with plerixafor plus Granulocyte Colony Stimulating Factor (G-CSF), according to investigator discretion, after 4 cycles of induction therapy. Study treatment interruption for stem cell collection were not to exceed 30 days. All patients were to receive one additional cycle of study treatment after stem cell collection and then proceed to autologous transplant using melphalan 200mg/m2(140mg/m2 for patients \> 70 years), as conditioning. After Autologus Stem Cell Transplant( ASCT), patients still on study were to initiate maintenance therapy within the 60-120 day period following ASCT, provided they have adequate blood count and clinical recovery. Patients in the RVD arm were to initiate maintenance therapy with lenalidomide alone, and patients in RVD-panobinostat arm were to receive lenalidomide + panobinostat maintenance. Lenalidomide were to be dosed orally at 10mg/day continuously in both arms, increasing to 15mg/day after the first 84 day cycle. Panobinostat were to be dosed at 10mg three times a week, every other week. Total planned duration of maintenance therapy were to be 3 years. Patients were to remain on study treatment until they complete the maintenance phase, or until they experience disease progression, unacceptable toxicity, or at the discretion of the Investigator.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a66cf585998df08c58bb
      requested nct id
      NCT02720510
      primary nct id
      NCT02720510
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      234a2d7042561b4fd5ce56f777b72f5633631fe13840cc052c61881dd7fbee18
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a66cf585998df08c58bb
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT02720510
      occurrences
      1. context exact
        NCT02720510
        end
        11
        exact text
        NCT02720510
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/886/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      bca2381d77174bd6216be654d238cdae2f377e4927931800ca8655540f7dcddb

    Preserved source evidence · Not medical advice